Drugplain

Cefdinir 300 mg/1

Cefdinir · CAPSULE · Proficient Rx LP

10 Recalls on Record
Plain English

Cefdinir is a capsule containing cefdinir at 300 mg/1, taken oral. Manufactured by Proficient Rx LP.

Key Facts

Brand Name
Cefdinir
Generic Name
Cefdinir
NDC Code (Product)
71205-576
Manufacturer
Proficient Rx LP
Strength
300 mg/1
Dosage Form
CAPSULE
Route
ORAL
Marketing Status
Application #
ANDA210220
Drug Class
Cephalosporin Antibacterial [EPC]
Marketing Start
02/20/2021

Recall History

10 Recalls on Record
Class II01/02/2019

Lupin Pharmaceuticals Inc.

CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to be thick.

TerminatedVoluntary: Firm initiated
Class II04/24/2024

Lupin Pharmaceuticals Inc.

Presence of foreign substance: Product complaint of foreign material in reconstituted bottle.

TerminatedVoluntary: Firm initiated
Class II03/27/2018

Lupin Pharmaceuticals Inc.

Superpotent Drug

TerminatedVoluntary: Firm initiated
Class II01/02/2019

Lupin Pharmaceuticals Inc.

CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to be thick.

TerminatedVoluntary: Firm initiated
Class II05/08/2024

Lupin Pharmaceuticals Inc.

Defective container: lack of seal integrity.

TerminatedVoluntary: Firm initiated
Class II07/02/2020

Lupin Pharmaceuticals Inc.

Superpotent Drug: Out-of-specification (OOS) result observed in an assay test of retention samples.

TerminatedVoluntary: Firm initiated
Class III11/01/2019

Lupin Pharmaceuticals Inc.

Presence of Foreign substance: identified as a dead ant.

TerminatedVoluntary: Firm initiated
Class III11/01/2019

Lupin Pharmaceuticals Inc.

Presence of Foreign substance: identified as a dead ant.

TerminatedVoluntary: Firm initiated
Class II02/26/2013

Teva Pharmaceuticals USA, Inc.

Defective Container: This recall is being carried out due to the potential for improperly sealed bottles.

TerminatedVoluntary: Firm initiated
Class II05/23/2019

Lupin Pharmaceuticals Inc.

Complaint received of metal piece identified in the product bottle prior to the reconstitution.

TerminatedVoluntary: Firm initiated

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

diarrhoea520 reports
chronic kidney disease485 reports
pneumonia476 reports
fatigue451 reports
nausea389 reports
pain373 reports
renal failure362 reports
sinusitis355 reports
acute kidney injury324 reports
headache324 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES ). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase

Dosage & Administration

DOSAGE AND ADMINISTRATION (see INDICATIONS AND USAGE for Indicated Pathogens) The recommended dosage and duration of treatment for infections in pediatric patients are described in the following chart; the total daily dose for all infections is 14 mg/kg, up to a maximum dose of 600 mg per day. Once-daily dosing for 10 days is as effective as BID dosing. Once-daily dosing has not been studied in skin infections; therefore, cefdinir for oral suspension should be administered twice daily in this infection. Cefdinir for oral suspension may be administered without regard to meals. Pediatric Patients (Age 6 Months Through 12 Years) Type of Infection Dosage Duration Acute Bacterial Otitis Media 7 mg/kg q12h or 14 mg/kg q24h 5 to 10 days 10 days Acute Maxillary Sinusitis 7 mg/kg q12h or 14 mg/kg q24h 10 days 10 days Pharyngitis/Tonsillitis 7 mg/kg q12h or 14 mg/kg q24h 5 to 10 days 10 days Uncomplicated Skin and Skin Structure Infections 7 mg/kg q12h 10 days CEFDINIR FOR ORAL SUSPENSION PEDIATRIC DOSAGE CHART a Pediatric patients who weigh ≥ 43 kg should receive the maximum daily dose of 600 mg. Weight 125 mg/5 mL 250 mg/5 mL 9 kg/20 lbs 2.5 mL q12h or 5 mL q24h Use 125 mg/5 mL product 18

Warnings

WARNINGS BEFORE THERAPY WITH CEFDINIR IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFDINIR, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF CEFDINIR IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-HYPERSENSITIVITY AMONG β-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO CEFDINIR OCCURS, THE DRUG SHOULD BE DISCONTINUED. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefdinir, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD.

Contraindications

CONTRAINDICATIONS Cefdinir is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.

Drug Interactions

Drug Interactions Antacids: ( aluminum- or magnesium-containing ) Concomitant administration of 300 mg cefdinir capsules with 30 mL Maalox ® TC suspension reduces the rate (C max ) and extent (AUC) of absorption by approximately 40%. Time to reach C max is also prolonged by 1 hour. There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir. If antacids are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the antacid. Probenecid As with other β-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in AUC, a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination t ½ . Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO 4 ) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. If iron supplements are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the supplement

Adverse Reactions

ADVERSE EVENTS Clinical Trials - Cefdinir Capsules (Adult and Adolescent Patients) In clinical trials, 5093 adult and adolescent patients (3841 U.S. and 1252 non-U.S.) were treated with the recommended dose of cefdinir capsules (600 mg/day). Most adverse events were mild and self-limiting. No deaths or permanent disabilities were attributed to cefdinir. One hundred forty-seven of 5093 (3%) patients discontinued medication due to adverse events thought by the investigators to be possibly, probably, or definitely associated with cefdinir therapy. The discontinuations were primarily for gastrointestinal disturbances, usually diarrhea or nausea. Nineteen of 5093 (0.4%) patients were discontinued due to rash thought related to cefdinir administration. In the U.S., the following adverse events were thought by investigators to be possibly, probably, or definitely related to cefdinir capsules in multiple-dose clinical trials (N = 3841 cefdinir-treated patients): ADVERSE EVENTS ASSOCIATED WITH CEFDINIR CAPSULES U.S. TRIALS IN ADULT AND ADOLESCENT PATIENTS (N = 3841) a a 1733 males, 2108 females Incidence ≥1% Diarrhea 15% Vaginal moniliasis 4% of women Nausea 3% Headache 2% Abdominal pain 1%

Frequently Asked Questions

What is Cefdinir used for?

Cefdinir contains Cefdinir. It is a capsule taken oral. Consult your doctor for specific uses.

Is Cefdinir a controlled substance?

Cefdinir is not classified as a controlled substance by the DEA.

What is the generic name for Cefdinir?

The generic name for Cefdinir is Cefdinir. There are 1 other brand versions of Cefdinir.

What is the NDC code for Cefdinir 300 mg/1?

The NDC (National Drug Code) for Cefdinir 300 mg/1 is 71205-576, listed by Proficient Rx LP.